Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multivirus-specific VSTs for EBV, CMV, Adenovirus Infections Post-HSCT
NCT02510417Phase 1Completed
- Sponsor
- Catherine Bollard
- Start
- Oct 2014
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in Epstein-Barr virus infection, cytomegalovirus infection (CMV) and adenovirus infection, sponsored by Catherine Bollard. Primary endpoint: Assessments of patients with adverse events after VSTs infusion at 45 days. Started Oct 2014; status: completed.
02
Conditions
Epstein-Barr virus infectioncytomegalovirus infection (CMV)adenovirus infection
Beyond the preview
Go deeper on NCT02510417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510417.